EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)

Ghislain Bérard, Chantal Guévremont, Nathalie Marcotte iD, Coleen Schroeder, Nicole Bouchard, Raghu Rajan, Programme de Gestion Thérapeutique des Médicaments (PGTM)

Current Oncology · 2023

DOI: 10.3390/curroncol30030247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Ghislain Bérard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie-Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie-CHUS), Sh…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since July 2017, pembrolizumab has been approved as a first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with a PD-L1 score ≥ 50% in Quebec. Study objectives were to describe and assess the real-world use of pembrolizumab; report progression-free survival (PFS), overall survival (OS), and immune-related adverse events (IRAEs); and compare outcomes between a fixed dose (FD) and a weight-based capped dose (WCD). Medical records of patients treated in one of Quebec’s four adult university teaching hospitals who received pembrolizumab between 1 November 2017 and 31 October 2019 were reviewed and followed until 29 February 2020. Two hundred and seventy-nine patients were included. The median real-world PFS and OS were 9.4 (95% CI, 6.6 to 11.2) and 17.3 months (95% CI, 12.9 to not reached), respectively. IRAEs causing delays or treatment interruptions were seen in 34.4% of patients. Initiating treatment with a FD (49 patients) or using a WCD (230 patients) does not appear to affect PFS, OS, or the occurrence of IRAEs. The use of a WCD strategy allowed approximately CAD 5.8 million in savings during the course of our study. These findings support the effectiveness and safety of pembrolizumab in a real-world setting. The use of a WCD does not appear to have a negative impact on patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultHumansB7-H1 AntigenHospitals, TeachingQuebecUniversitiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

anti-PD-1immunotherapynon-small cell lung cancerpembrolizumabreal-world data

Substanzen

Antineoplastic Agents, ImmunologicalB7-H1 AntigenpembrolizumabAntibodies, Monoclonal, HumanizedCD274 protein, human

Autor:innen und Institutionen

  • Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie-Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie-CHUS), Sherbrooke, QC J1G 1B1, Canada.
  • McGill University Health Center (MUHC), Montréal, QC H4A 3J1, Canada.
  • CHU de Québec-Université Laval, Québec, QC G1R 2J6, Canada.

ORCID-Profile: Nathalie Marcotte

Zitieren

APA

Bérard, G., Guévremont, C., Marcotte, N., Schroeder, C., Bouchard, N., Rajan, R., & Programme de Gestion Thérapeutique des Médicaments (PGTM) (2023). Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study). Current Oncology. https://doi.org/10.3390/curroncol30030247

Vancouver

Bérard G, Guévremont C, Marcotte N, Schroeder C, Bouchard N, Rajan R, et al. Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study). Current Oncology. 2023. doi:10.3390/curroncol30030247

BibTeX
@article{Brard2023,
  author = {Bérard, Ghislain and Guévremont, Chantal and Marcotte, Nathalie and Schroeder, Coleen and Bouchard, Nicole and Rajan, Raghu and Programme de Gestion Thérapeutique des Médicaments (PGTM), Programme de Gestion Thérapeutique des Médicaments (PGTM)},
  title = {Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30030247}
}
Kostenlos starten →